- Home
- NXPL vs LTRN Comparison
NXPL vs LTRN Comparison
Compare NXPL & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | LTRN |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 27.6M |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NXPL | LTRN |
|---|---|---|
| Price | $9.34 | $1.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.7K | ★ 162.3K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,869,558.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.50 | N/A |
| 52 Week Low | $0.34 | $1.11 |
| 52 Week High | $9.94 | $4.70 |
Technical Indicators
Market Signals| Indicator | NXPL | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 25.12 |
| Support Level | $8.70 | $1.11 |
| Resistance Level | $9.94 | $2.41 |
| Average True Range (ATR) | 0.56 | 0.15 |
| MACD | -0.08 | -0.00 |
| Stochastic Oscillator | 50.24 | 0.00 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.